S
Silvio Danese
Researcher at Humanitas University
Publications - 1184
Citations - 47449
Silvio Danese is an academic researcher from Humanitas University. The author has contributed to research in topics: Ulcerative colitis & Medicine. The author has an hindex of 90, co-authored 893 publications receiving 35801 citations. Previous affiliations of Silvio Danese include The Catholic University of America & Catholic University of the Sacred Heart.
Papers
More filters
Journal ArticleDOI
Gastroenterology department operational reorganisation at the time of covid-19 outbreak: an Italian and Chinese experience.
Silvio Danese,Zhi Hua Ran,Alessandro Repici,Jinlu Tong,Paolo Omodei,Alessio Aghemo,A. Malesci +6 more
TL;DR: Covid-19 clinical presentation is similar to that of other types of pneumonia, namely flu-like manifestations, such as fever and cough, possibly evolving to severe hypoxaemia, ARDS and hypoxic respiratory failure.
Journal ArticleDOI
Transmural healing as a therapeutic goal in Crohn's disease: a systematic review
Sophie Geyl,Lucas Guillo,Valérie Laurent,Ferdinando D'Amico,Silvio Danese,Laurent Peyrin-Biroulet +5 more
TL;DR: Transmural healing is associated with substantial improvements in disease-related outcomes for patients with Crohn's disease, but there is no single validated definition of transmural healing to date as mentioned in this paper.
Journal ArticleDOI
Redox Equilibrium in Mucosal T Cells Tunes the Intestinal TCR Signaling Threshold
TL;DR: The high TCR signaling threshold of mucosal T cells is tuned by intracellular redox equilibrium, whose dysregulation may mediate intestinal inflammation.
Journal ArticleDOI
Calcium supplementation for the prevention of colorectal adenomas : A systematic review and meta-analysis of randomized controlled trials
TL;DR: A systematic review and meta-analysis of published studies suggests a modest chemopreventive effect of calcium supplements against recurrent colorectal adenomas over a period of 36 to 60 mo.
Journal ArticleDOI
Infection Risk With Biologic Therapy in Patients With Inflammatory Bowel Disease
TL;DR: Current evidence on the infection risk associated with biologic therapy in patients with inflammatory bowel disease (IBD) is reviewed and discussed.